Literature DB >> 743203

Activation of the first component of human complement (C1) by antibody-antigen aggregates.

A W Dodds, R B Sim, R R Porter, M A Kerr.   

Abstract

The activation of subcomponents C1r and C1s in the first component of complement, C1, when bound to antibody-antigen complexes was investigated. Activation was followed both by the splitting of the peptide chains of subcomponents C1r and C1s and by the development of proteolytic activity. For the maximum rate of activation to occur, all components must be present in approximate molar proportions of antibody: C1q:C1r:C1s of 13:1:5:5. For activation of subcomponent C1s, subcomponents C1r or C1r, but not C1r inactivated with iPr2P-F (di-isopropyl phosphorofluorideate), are effective. For activation of subcomponent C1r, subcomponents C1s, C1s or C1s inactivated with iPr2P-F are effective. Subcomponent C1s is activated by C1r, and C1r is activated autocatalytically, probably through the formation of an intermediary C1r. in which the peptide chain is unsplit but a conformational change caused by interaction with the other components has led to the formation of a catalytic site able to split subcomponent C1r to C1r.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 743203      PMCID: PMC1186083          DOI: 10.1042/bj1750383

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  20 in total

1.  Concerning the mechanism of complement action. I. Inhibition of complement activity by diisopropyl fluophosphate.

Authors:  E L BECKER
Journal:  J Immunol       Date:  1956-12       Impact factor: 5.422

2.  Human factor D of the alternative complement pathway: purification and characterization.

Authors:  J E Volanakis; R E Schrohenloher; R M Stroud
Journal:  J Immunol       Date:  1977-07       Impact factor: 5.422

3.  The unactivated form of the first component of human complement, C1.

Authors:  I Gigli; R R Porter; R B Sim
Journal:  Biochem J       Date:  1976-09-01       Impact factor: 3.857

4.  Evidence that C1t (amyloid P-component) is not a subcomponent of the first component of complement (C1).

Authors:  R H Painter
Journal:  J Immunol       Date:  1977-12       Impact factor: 5.422

5.  Proenzymic C1s associated with catalytic amounts of C1r. Study of the activation process.

Authors:  G J Arlaud; A Reboul; M G Colomb
Journal:  Biochim Biophys Acta       Date:  1977-11-23

Review 6.  The eleventh Hopkins Memorial Lecture: The biochemistry of complement.

Authors:  R R Porter
Journal:  Biochem Soc Trans       Date:  1977       Impact factor: 5.407

7.  Studies on the precursor form of the first component of complement. II. Proteolytic fragmentation of Clr.

Authors:  S N Assimeh; R M Chapuis; H Isliker
Journal:  Immunochemistry       Date:  1978-01

8.  Purification of proenzymic and activated human C1s free ofC1r. Effect of calcium and ionic strength on activated C1s.

Authors:  G J Arlaud; A Reboul; C M Meyer; M G Colomb
Journal:  Biochim Biophys Acta       Date:  1977-11-23

9.  The structure and enzymic activities of the C1r and C1s subcomponents of C1, the first component of human serum complement.

Authors:  R B Sim; R R Porter; K B Reid; I Gigli
Journal:  Biochem J       Date:  1977-05-01       Impact factor: 3.857

10.  Chromatographic resolution of the first component of human complement into three activities.

Authors:  I H LEPOW; G B NAFF; E W TODD; J PENSKY; C F HINZ
Journal:  J Exp Med       Date:  1963-06-01       Impact factor: 14.307

View more
  26 in total

1.  Isolation and functional characterization of the proenzyme form of the catalytic domains of human C1r.

Authors:  M B Lacroix; C A Aude; G J Arlaud; M G Colomb
Journal:  Biochem J       Date:  1989-02-01       Impact factor: 3.857

2.  Modification of beta-2-microglobulin in sera from patients with small cell lung cancer: evidence for involvement of a serine protease.

Authors:  M H Nissen; O J Bjerrum; T Plesner; M Wilken; M Rørth
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

3.  Structure and activation of C1, the complex initiating the classical pathway of the complement cascade.

Authors:  Simon A Mortensen; Bjoern Sander; Rasmus K Jensen; Jan Skov Pedersen; Monika M Golas; Jens C Jensenius; Annette G Hansen; Steffen Thiel; Gregers R Andersen
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-19       Impact factor: 11.205

4.  C3 binds covalently to the C gamma 3 domain of IgG immune aggregates during complement activation by the alternative pathway.

Authors:  L C Antón; J M Alcolea; P Sánchez-Corral; G Marqués; A Sánchez; F Vivanco
Journal:  Biochem J       Date:  1989-02-01       Impact factor: 3.857

5.  Interactions of complement proteins C1q and factor H with lipid A and Escherichia coli: further evidence that factor H regulates the classical complement pathway.

Authors:  Lee Aun Tan; Andrew C Yang; Uday Kishore; Robert B Sim
Journal:  Protein Cell       Date:  2011-05-15       Impact factor: 14.870

Review 6.  Activation of the complement system.

Authors:  W Vogt
Journal:  Agents Actions       Date:  1983-08

7.  Autoactivation of human complement subcomponent C1r involves structural changes reflected in modifications of intrinsic fluorescence, circular dichroism and reactivity with monoclonal antibodies.

Authors:  C L Villiers; G J Arlaud; M G Colomb
Journal:  Biochem J       Date:  1983-11-01       Impact factor: 3.857

8.  Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies.

Authors:  P Vanguri; C L Koski; B Silverman; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

9.  Human complement component C4. Structural studies on the fragments derived from C4b by cleavage with C3b inactivator.

Authors:  E M Press; J Gagnon
Journal:  Biochem J       Date:  1981-11-01       Impact factor: 3.857

10.  The catalytic chain of human complement subcomponent C1r. Purification and N-terminal amino acid sequences of the major cyanogen bromide-cleavage fragments.

Authors:  G J Arlaud; J Gagnon; R R Porter
Journal:  Biochem J       Date:  1982-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.